For the year ending 2025-12-31, NEO has $1,359,830K in assets. $523,268K in debts. $159,618K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 159,618 | |||
| Marketable securities, at fair value | 0 | |||
| Accounts receivable, net | 159,242 | |||
| Inventories | 28,566 | |||
| Prepaid assets | 21,443 | |||
| Other current assets | 7,417 | |||
| Total current assets | 376,286 | |||
| Property and equipment (net of accumulated depreciation of 209,057 and 189,990, respectively) | 84,834 | |||
| Operating lease right-of-use assets | 78,444 | |||
| Total cost of intangibles | 467,418 | |||
| Accumulated amortization | 180,890 | |||
| Intangible assets, net | 286,528 | |||
| Goodwill | 524,344 | |||
| Other assets | 9,394 | |||
| Total non-current assets | 983,544 | |||
| Total assets | 1,359,830 | |||
| Accounts payable | 23,090 | |||
| Accrued compensation | 47,580 | |||
| Accrued expenses and other liabilities | 12,003 | |||
| Current portion of operating lease liabilities | 4,776 | |||
| Current portion of convertible senior notes, net | 0 | |||
| Contract liabilities | 851 | |||
| Total current liabilities | 88,300 | |||
| Operating lease liabilities | 62,822 | |||
| Convertible senior notes, net | 341,858 | |||
| Deferred income tax liabilities, net | 18,219 | |||
| Other long-term liabilities | 12,069 | |||
| Total long-term liabilities | 434,968 | |||
| Total liabilities | 523,268 | |||
| Common stock, 0.001 par value, (250,000,000 shares authorized 128,989,152 and 128,145,333 shares issued and outstanding, respectively) | 129 | |||
| Additional paid-in capital | 1,270,235 | |||
| Accumulated other comprehensive income (loss) | 4 | |||
| Accumulated deficit | -433,806 | |||
| Total stockholders equity | 836,562 | |||
| Total liabilities and stockholders' equity | 1,359,830 | |||
NEOGENOMICS INC (NEO)
NEOGENOMICS INC (NEO)